Latest Capital Raises News

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Stealth Group Holdings has delivered record half-year results for 1H26, boosted by its strategic acquisition of Hardware & Building Traders and a strengthened balance sheet. The company is now targeting over $500 million in sales by FY28, signalling ambitious growth in Australia's fragmented hardware and industrial distribution market.

MA Credit Income Trust reported a strong half-year profit of $19.7 million, exceeding its return target, while successfully completing a $190.5 million capital raise and initiating a strategic buy-back to manage liquidity.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.

Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.

AuMEGA Metals has confirmed a $30 million oversubscribed financing led by Condire Investors to fund expanded drilling and exploration in Newfoundland. The capital raise is structured in two tranches, with the first closing expected in early March and the second pending shareholder approval.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Bapcor Limited has postponed its half-year financial results release to no later than 27 February 2026 and is seeking an extension of its trading suspension, hinting at a potential capital raising.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.